



MedImmune

William C. Bertrand, Jr.
Senior Vice President and General Counsel
(301) 398-4625
bertrandw@medimmune.com

December 28, 2006

SUBMITTED ELECTRONICALLY

Division of Dockets Management
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, Maryland 20852

Re: Docket No. 2006P-0410

Dear Sir or Madam:

On December 21, 2006, Winston & Strawn LLP, on behalf of Sun Pharmaceutical Industries, Ltd., submitted comments in opposition to the above-referenced citizen petition. Unfortunately, a copy of the comments was not available from the Division of Dockets Management until today.

Because the comments raise substantive issues that go directly to the merits of the petition, we are writing to notify FDA that MedImmune intends to submit a response in the near future, and to ask that no action be taken on our petition until the agency has had an opportunity to review and consider our response, in order to ensure that the record is complete and FDA has before it all relevant information.

Thank you for your consideration.

Respectfully submitted,

William C. Bertrand, Jr.

cc: Paul Seligman (paul.seligman@fda.hhs.gov)
David Read (david.read@fda.hhs.gov)
Nancy Boocker (nancy.boocker@fda.hhs.gov)